BioVersys AG
BIOV
Company Profile
Business description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others.
Contact
c/o Technologiepark
Hochbergerstrasse 60c
BaselCH-4057
CHET: +41 615515120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,399.80 | 30.50 | 0.36% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 40,863.90 | 34.90 | 0.09% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,691.88 | 29.17 | 0.13% |
| NASDAQ | 17,524.04 | 165.62 | -0.94% |
| Nikkei 225 | 36,779.66 | 51.03 | -0.14% |
| NZX 50 Index | 12,496.89 | 75.80 | 0.61% |
| S&P 500 | 5,582.79 | 24.12 | -0.43% |
| S&P/ASX 200 | 8,178.30 | 26.90 | 0.33% |
| SSE Composite Index | 3,342.67 | 26.55 | 0.80% |